KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) Equity Average (2016 - 2025)

Charles River Laboratories International has reported Equity Average over the past 16 years, most recently at $3.3 billion for Q4 2025.

  • Quarterly results put Equity Average at $3.3 billion for Q4 2025, down 9.29% from a year ago — trailing twelve months through Dec 2025 was $3.3 billion (down 9.29% YoY), and the annual figure for FY2025 was $3.3 billion, down 6.12%.
  • Equity Average for Q4 2025 was $3.3 billion at Charles River Laboratories International, down from $3.4 billion in the prior quarter.
  • Over the last five years, Equity Average for CRL hit a ceiling of $3.8 billion in Q3 2024 and a floor of $2.2 billion in Q1 2021.
  • Median Equity Average over the past 5 years was $3.2 billion (2023), compared with a mean of $3.0 billion.
  • Biggest five-year swings in Equity Average: skyrocketed 32.21% in 2021 and later dropped 11.03% in 2025.
  • Charles River Laboratories International's Equity Average stood at $2.5 billion in 2021, then rose by 12.93% to $2.8 billion in 2022, then rose by 23.14% to $3.5 billion in 2023, then grew by 4.85% to $3.6 billion in 2024, then fell by 9.29% to $3.3 billion in 2025.
  • The last three reported values for Equity Average were $3.3 billion (Q4 2025), $3.4 billion (Q3 2025), and $3.3 billion (Q2 2025) per Business Quant data.